Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
In ATTAIN-MAINTAIN, patients who had plateaued after injectable therapy switched to oral orforglipron, marketed as Foundayo
Phase 2 results are promising
Key cited studies: Teichman SL et al
Weight changes can be influenced by appetite signals, blood sugar patterns, sleep quality, stress load, and the way your body responds to routine over time
Key Takeaways Tirzepatide (Zepbound) produces greater average weight loss than semaglutide (Wegovy) across both clinical trials and the first direct head-to-head comparison, 20.9% versus 14.9% in separate Phase 3 trials, and 20.2% versus 13.7% in the SURMOUNT-5 trial published in the New England Journal of Medicine
US$ 21.91
US$ 21.71
US$ 25.92
US$ 25.66
US$ 28.72
US$ 27.74
US$ 25.95
US$ 28.04
US$ 26.69
